Lung cancer is the most frequent solid tumour and represents the leading cause of cancer death throughout the developed world. Almost 70% of patients with non-small-cell lung carcinoma (NSCLC) present with locally advanced or metastatic disease at the time of diagnosis. Non-small-cell lung carcinoma is characterised by the accumulation of multiple genetic alterations ([Marsit *et al*, 2004](#bib30){ref-type="other"}; [Yokota and Kohno, 2004](#bib49){ref-type="other"}; [Garnis *et al*, 2006](#bib15){ref-type="other"}). Mutations within the tyrosine kinase domain of epidermal growth factor receptor (*EGFR*) account for increased sensitivity to tyrosine kinase inhibitors (TKIs; gefitinib and erlotinib) and they are associated with prolonged overall survival ([Lynch *et al*, 2004](#bib29){ref-type="other"}; [Paez *et al*, 2004](#bib32){ref-type="other"}; [Perez-Soler *et al*, 2004](#bib36){ref-type="other"}; [Chou *et al*, 2005](#bib7){ref-type="other"}; [Taron *et al*, 2005](#bib41){ref-type="other"}; [Hirsch, 2006](#bib19){ref-type="other"}). However, the point mutation T790M and an insertion mutation in exon 20 were associated with resistance to TKIs ([Gazdar and Minna, 2005](#bib16){ref-type="other"}). Furthermore, recent studies have shown that the expression of EGFR as assessed by gene copy number, mRNA and protein levels could be used to predict responsiveness to therapy with TKIs ([Hirsch *et al*, 2005](#bib21){ref-type="other"}; [Taron *et al*, 2005](#bib41){ref-type="other"}; [Dacic *et al*, 2006](#bib9){ref-type="other"}; [Dziadziuszko *et al*, 2006](#bib11){ref-type="other"}; [Endo *et al*, 2006](#bib12){ref-type="other"}). In addition, several clinicopathological characteristics, such as adenocarcinoma histology, non-smoking history, female gender and Asian origin, are also associated with a higher probability of response to TKIs, whereas the presence of *K-RAS* mutations seems to be correlated with primary resistance to these agents ([Tokumo *et al*, 2005](#bib42){ref-type="other"}; [Tsao *et al*, 2005](#bib45){ref-type="other"}; [van Zandwijk *et al*, 2007](#bib47){ref-type="other"}). Thus, an emerging issue concerning EGFR-targeted therapy is to identify the best method for selecting patients who are more likely to benefit from EGFR inhibition.

Advanced NSCLC metastasises systemically to diverse sites, such as the brain, bone, adrenal glands and liver. The classical model for the metastatic process suggests that most cells of a given primary tumour have low metastatic potential and only a few cells acquire enough somatic mutations to become metastatic ([Bernards and Weinberg, 2002](#bib2){ref-type="other"}). An alternative model proposes that the metastatic potential is encoded in the mass of a given primary tumour that has progressed to a pre-metastatic state, after which metastases may randomly occur without any further gene expression changes ([van 't Veer *et al*, 2002](#bib46){ref-type="other"}; [Hynes, 2003](#bib23){ref-type="other"}; [Van\'t Veer and Weigelt, 2003](#bib48){ref-type="other"}). Taking into account these two models, a critical issue for the treatment of metastatic NSCLC is the question of genetic variability and differences between the primary tumour and the corresponding metastases. In the majority of studies, *EGFR* and *K-RAS* status was determined on the primary tumours and there are very few data concerning those of corresponding metastases ([Italiano *et al*, 2006](#bib24){ref-type="other"}; [Matsumoto *et al*, 2006](#bib31){ref-type="other"}). Therefore, it is unclear whether the same *EGFR* and *K-RAS* mutations are also present in the metastatic lesions or whether clones with different mutations are responsible for the generation of metastases.

In this study, the mutation status of *EGFR* and *K-RAS* as well as the EGFR and p-EGFR expressions on the primary tumours and the corresponding metastatic lesions were evaluated in 25 patients with advanced NSCLC. The objective of this study was to investigate the prevalence of *EGFR* and *K-RAS* mutations in metastases and to examine whether these mutations and the EGFR expression patterns are discordant between the primary tumours and the corresponding metastases. Secondary objectives were to explore whether the EGFR expression pattern correlated to *EGFR* and/or *K-RAS* mutations in both the primary tumours and corresponding metastases.

Patients and methods
====================

Patients
--------

Patients, aged \>18 years old, with histologically confirmed NSCLC who underwent biopsy or surgical excision of the primary tumour and the corresponding metastases were included in this retrospective analysis. Histological type was determined according to the World Health Organization criteria, and the stage of the disease corresponds to that of the time of primary diagnosis. Smoking history was obtained during the patient\'s first evaluation. All patients gave their informed consent for using their tumour sample for molecular and pathologic analysis. The study has been approved by the Ethics and Scientific Committees of our institution.

DNA extraction and mutation analysis
------------------------------------

All tumour samples were formalin-fixed paraffin-embedded tissues. Sections of a paraffin block corresponding to one representative area of the tumour were stained with haematoxylin/eosin, and the presence of tumour tissue was verified by an experienced pathologist. Subsequently, tissue samples from at least three serial sections were microdissected (piezo power Eppendorf Microdissector; Eppendorf, Germany) to ensure that specimens contained at least 80% tumour cells; sections of 5 *μ*m thickness were also collected from adjacent normal tissue when available, extracted with xylene and ethanol to remove paraffin and placed in 1% SDS/proteinase K (10 mg ml^−1^) at 56°C overnight. DNA was extracted using the MasterPure Complete DNA/RNA Purification kit (Epicentre Biotechnologies, Madison, WI, USA) according to the manufacturer\'s instructions. Exons 18, 19, 20 and 21 of the EGFR and exon 1 of K-RAS were sequentially amplified by two rounds of polymerase chain reaction (PCR) and subjected to direct sequencing. The PCR primers for *EGFR* amplification were as follows: 155273L23: 5′-TCCCAAACACTCAGTGAAACAAA-3′; 155348L22: 5′-TGGTCTCACAGGACCACTGATT-3′; 154838U22: 5′-TCAGAGCCTGTGTTTCTACCAA-3′; 154899U20: 5′-TCCAAATGAGCTGGCAAGTG-3′; 55634U24: 5′-AAATAATCAGTGTGATTCGTGGAG-3′; 156027L20: 5′-TGTGGAGATGAGCAGGGTCT-3′; 156107L22: 5′-GAGGCCAGTGCTGTCTCTAAGG-3′; 155750U20: 5′-GTGCATCGCTGGTAACATCC-3′; 173160L22: 5′-CAGCTCTGGCTCACACTACCAG-3′; 173076L19: 5′-CATCCTCCCCTGCATGTGT-3′; 172656U22: 5′-GCAGCGGGTTACATCTTCTTTC-3′; and 172747U19: 5′-GCT CAGAGCCTGGCATGAA-3′. The PCR primers for *K-RAS* amplification were as follows: RASU1: 5′-AGGCCTGCTGAAAATGACTGAATA-3′; RASL1: 5′-CTGTATCAAAGAATGGTCCTGCAC-3′; RASU2: 5′-AAAATGACTGAATATAAACTTGTGG-3′; RASL2: 5′-CTCTATTGTTGGATCATATTCGTC-3′. The first PCR was carried out in a total volume of 10 *μ*l contained 1/10 of the extracted genomic DNA using 1 U of Platinum Taq DNA polymerase (Invitrogen Corporation, Carlsbad, CA, USA). The initial denaturing step was at 94°C for 15 min, followed by 35 cycles of denaturing step at 94°C for 20 s, annealing step at 60°C for 30 s and extension step at 72°C for 1 min, ending with a final extension step at 72°C for 7 min. Nested PCR was carried out in a total volume of 20 *μ*l and the conditions were identical to the first PCR. The PCR products are directly sequenced by dye terminator sequencing (ABI BigDye Terminator kit, v3.1, Applied Biosystems, Foster City, CA, USA), purified by ethanol precipitation and separated by capillary electrophoresis on an ABI 3100 Avant genetic analyzer (Applied Biosystems). Sequence analysis was carried out by Seqscape software (Applied Biosystems) and manually by two reviewers (AK and AV). All sequence variations were confirmed by sequencing in both directions and by an independent PCR amplification when sufficient material was available.

The sensitivity of our methodology was evaluated by determining the minimum frequency of *EGFR* and *K-RAS* mutations required for detection in our system. This was accomplished by performing mixing experiments using cell lines with and without *EGFR* (H2073-wt-*EGFR* and HCC827-Del19-*EGFR*) or *K-RAS* (H2073-wt-*K-RAS* and A549-G12D-*K-RAS*) mutations. These experiments demonstrated that the Del19 and *K-RAS* mutations could be detected when present in 10 and 20% of the cells in the sample, respectively (data not shown).

Immunohistochemistry for EGFR
-----------------------------

The paraffin-embedded tissues were cut at 4 *μ*m thickness and were deposited on SuperFrost/Plus Slides (O.Kindler GmbH, Freiburg, Germany). After deparaffinisation, the slides for EGFR were treated with proteinase K (Code S3020, DakoCytomation, Glostrup, Denmark) for 5 min at room temperature, and those for p-EGFR were treated with EDTA at pH 8 in a microwave oven three times for 5 min at 500 W for antigen retrieval. The primary anti-EGFR antibody (mouse monoclonal, clone H11, code M3563, DakoCytomation) was used at a dilution of 1 : 50 (v/v) and incubated for 1 h at room temperature. The primary anti-phospho-EGFR antibody (rabbit monoclonal, pY1173-EGFR, code no. 4407, Cell Signalling, Danvers, MA, USA) was used at a dilution of 1 : 200 (v/v) and incubated overnight at 4°C. For the detection of antigen-antibody reaction, the UltraVision detection system AP Polymer kit (Cat no. TL-125-AL, Lab Vision, Fremont, CA, USA) was used according to the manufacturer\'s instructions. Fast red was used as chromogen for 20 min; the sections were counterstained with Mayer\'s haematoxylin for 3 min, subsequently rinsed in ammonium and finally mounted with glycergel. A positive (an NSCLC tumour specimen with known positivity) and a negative (omission of primary antibody) control were used. The stained sections were independently evaluated by two pathologists (AK and ES). Immunoreactions of EGFR were graded as 3+ when strong complete membrane staining was observed in more than 10% of the tumour cells, as 2+ when more than 10% of the tumour cells showed weak-to-moderate complete membrane staining, as 1+ when partially, faint membrane stain was detected in more than 10% of the tumour cells and as 0 when no staining at all or membrane staining in less than 10% of the tumour cells was observed. In this study, we arbitrarily classified EGFR expression status in two subsets; the 2+ or 3+ signals were considered as EGFR overexpression and the 0 or 1+ signals as non-expression ([Koutsopoulos *et al*, 2007](#bib25){ref-type="other"}).

A paraffin block from the HCC827 lung epithelial adenocarcinoma cell line and commercially available positive controls (SignalSlide Phospho-EGF Receptor (Tyr1173) IHC Controls, code no. 8102, Cell Signalling) was used to validate the antibody for p-EGFR. pY1173-EGFR immunostaining was mainly membranous and was graded as 0 (\<5% positive cells), 1+ (5--19% positive cells), 2+ (20--50% positive cells) and 3+ (\>50% positive cells) ([Cortas *et al*, 2007](#bib8){ref-type="other"}).

Statistical analysis
--------------------

McNemar test was used to compare the *EGFR* and *K-RAS* status between primary tumours and related metastatic sites. Differences were considered statistically significant when the *P*-value was \<0.05. All statistical tests were two-sided.

Results
=======

Patient characteristics
-----------------------

Twenty-two (88%) patients were men and 22 (88%) were active or former smokers and their median age was 55 years (range, 41--70). Eighteen (72%) patients had adenocarcinomas (ADC) and 21 (84%) patients had stage III or IV disease. Among the 50 samples analysed (25 primary tumours and 25 metastases), 26 (52%) samples were surgical and 24 (48%) biopsies. The primary tumour tissue was the lung (*n*=25 patients); and the origin of the metastatic sample was lung (*n*=9 patients), thoracic wall (*n*=5 patients), adrenal gland (*n*=4 patients), brain (*n*=3 patients), bone (*n*=2 patients), liver (*n*=1 patient) and skin (*n*=1 patient). Metastases were metachronous in all cases; the median time elapsed between resection of the primary tumour and the corresponding metastatic site was 30 months (range, 4--143). The patients\' clinicopathologic characteristics are presented in [Table 1](#tbl1){ref-type="table"}. Nine (36%) patients were treated with gefitinib in the context of an Expanded Access Program ([Table 2](#tbl2){ref-type="table"}).

*EGFR* mutation status of the primary tumours and the corresponding metastasis
------------------------------------------------------------------------------

The *EGFR* mutation status of the primary tumours and the corresponding metastases is presented in [Table 2](#tbl2){ref-type="table"}. Epidermal growth factor receptor mutations were detected in the primary tumours of five (20%) patients; of these, three of them were the well-characterised 'hotspot\' mutations in exon 19 (Del746-750 and E746V; case nos. 20, 23 and 18) and the remaining two were novel point mutations in exons 18 and 21 (L692P and G857E; case nos. 17 and 19), respectively. The corresponding metastases of the Del746-750 (case no. 23), E746V (no. 18), L692P (no. 17) and G857E (no. 19) mutant primary tumours were wild type with respect to *EGFR* mutation status. Epidermal growth factor receptor mutations were detected in the metastatic tumours of three (12%) patients ([Table 2](#tbl2){ref-type="table"}). The metastasis of one of these patients showed the same *EGFR* mutation (Del19) as the primary tumour as well as an additional one, the T790M in exon 20 (no. 20); conversely, the other two patients carried two novel mutations in exon 18 (L692P and V717A; no. 12) and the T847A (no. 13) in exon 21, which could not be detected in the patients\' primary tumour samples. We have confirmed that the non-classical mutations detected in our series are not single nucleotide polymorphisms by mutation analysis of matched normal tissue or blood (data not shown).

Consequently, the *EGFR* gene status could be classified as: (i) *EGFR* wild type in both primary tumour and metastasis (*n*=18 patients; 72%), and (ii) *EGFR* mutations detected only in the primary tumour (*n*=4 patients; 16%) or the metastases (*n*=2 patients; 8%) or both (*n*=1 patient; 4%). Therefore, *EGFR* mutation status showed a discordance of 28% (7 of 25 patients) (McNemar test, *P*=0.688) between the primary tumour and corresponding metastasis ([Table 3](#tbl3){ref-type="table"}).

EGFR and p-EGFR expression by IHC in the primary tumour and the corresponding metastases
----------------------------------------------------------------------------------------

Én 19 patients sufficient tumour tissue was available for immunohistochemical analysis of EGFR ([Tables 2](#tbl2){ref-type="table"} and [4](#tbl4){ref-type="table"}). The incidence of EGFR overexpression (grade 2+, 3+) was 26.5% in both primary and metastatic tumours. Concordance between the primary tumour and the corresponding metastases was observed in 17 (89.5) patients (Cohen\'s Kappa=0.729, *P*=0.001) and among them EGFR was overexpressed in four (21.1%). Discordance was observed in two (10.5%) patients (nos. 14 and 15) (McNemar test, *P*=1). Evaluable paired tissue specimens for p-EGFR analysis by IHC were available in 16 patients. Three out of 16 (18.8%) primary and seven out of 16 (43.8%) metastatic tumours expressed phosphorylated EGFR (pY1173-EGFR-positive). Discordance between the primary and metastatic tumours was observed in eight (50%) patients (McNemar test, *P*=1) ([Tables 2](#tbl2){ref-type="table"} and [4](#tbl4){ref-type="table"}). There was no correlation between the expression of EGFR and pY1173-EGFR. In order to confirm our findings, we repeated the immunohistochemistry from serial sections in all tumour specimens that exhibited EGFR-negative and p-EGFR-positive staining and the obtained results were identical. Epidermal growth factor receptor gene copy number was also investigated by fluorescence *in situ* hybridisation in eight patients (nos. 2, 5, 7, 9, 10, 13, 19 and 24) for whom paired tissue specimens were available; amplification of *EGFR* gene was not detected in any of these tumour specimens.

*K-RAS* mutation status of the primary tumours and the corresponding metastases
-------------------------------------------------------------------------------

Primary and metastatic tumours were also assessed for *K-RAS* mutations ([Table 2](#tbl2){ref-type="table"}). *K-RAS* mutations were detected in the primary tumours of five (20%) patients (nos. 8, 10, 22, 23 and 25) and in the metastatic tumours of five (20%) patients (nos. 9, 10, 11, 16 and 23), respectively. Two patients (nos. 10 and 23) carried the same *K-RAS* mutations in both primary and metastatic tumours ([Table 2](#tbl2){ref-type="table"}). One of them (case no. 23) carried the Del746-750 EGFR mutation in the primary tumour but not in metastasis. This was confirmed by three independent PCRs from three genomic DNAs extracted from serial sections of the paraffin blocks. Discordance in *K-RAS* mutation status between the primary tumours and the corresponding metastases was observed in six (24%) patients (McNemar test, *P*=1) ([Table 3](#tbl3){ref-type="table"}).

Response to gefitinib according to *EGFR* and *K-RAS* mutation status
---------------------------------------------------------------------

Nine patients received gefitinib as first (nos. 23 and 18), third (nos. 15, 16, 19 20 and 22) or fourth (nos. 14 and 17) line treatment. Three patients received gefitinib before the biopsy of metachronous metastases (nos. 17, 18 and 20) and six received gefitinib after the biopsy of metastases (nos. 14, 15, 16, 19, 22 and 23). Five patients (56%) achieved stable disease and four (44%) progressive disease ([Table 2](#tbl2){ref-type="table"}). All patients who experienced progressive disease on gefitinib were wild type regarding the *EGFR* mutation status in both primary tumours and metastases (nos. 14, 15, 16, and 22), of these, two patients carried *K-RAS* mutations in the primary tumour (no. 22) or metastasis (no. 16). All the five patients with stable disease on gefitinib carried EGFR mutations in their primary tumours (nos. 17, 18, 19, 20 and 23). Of these, three patients carried the well-characterised activating mutations in exon 19 (nos. 18, 20 and 23) and two carried *EGFR* mutations of unknown function (nos. 17 and 19). Patient nos. 18 and 20 who received gefitinib before metachronous metastasis developed metastatic tumours, which were either wild type in respect to *EGFR* mutation status (no. 18) or had acquired resistance because of the T790M *EGFR* mutation (no. 20). Patient no. 23, who received gefitinib after metastasis, carried both *EGFR* and *K-RAS* mutations in the primary tumour and the same *K-RAS* mutation in metastasis.

Discussion
==========

Several studies have shown that activating *EGFR* mutations in exons 18, 19 and 21 have been associated with a 75--95% objective response rate with EGFR TKIs, whereas the *K-RAS* mutations were associated with a lack of sensitivity to these agents ([Pao *et al*, 2005](#bib34){ref-type="other"}; [Sharma *et al*, 2007](#bib38){ref-type="other"}). Epidermal growth factor receptor gene amplification and protein expression have also been considered as predictors of clinical benefit with gefitinib ([Hirsch *et al*, 2006](#bib20){ref-type="other"}). However, in clinical studies, a significant percentage of patients presented clinical benefit when treated with TKIs irrespective of the expression and mutational status of *EGFR* ([Sharma *et al*, 2007](#bib38){ref-type="other"}). As, in most studies, *EGFR* expression and mutations were determined on the primary tumour, the observed clinical benefit of patients with wild-type *EGFR* or the absence of response to TKIs of patients with *EGFR* mutations could be due to discordance in the *EGFR* mutation status or expression between the primary tumour and the corresponding metastasis.

This study demonstrated the existence of a significant discordance of *EGFR* and *K-RAS* mutations occurring in primary tumours and their corresponding metastases in patients with NSCLC. The discordance in *EGFR* mutation status was 28% and that in *K-RAS* was 24%. Similarly, two other studies in paired NSCLC tumours showed a discordance of 32 and 27% regarding the *EGFR* gene copy number ([Italiano *et al*, 2006](#bib24){ref-type="other"}; [Bozzetti *et al*, 2008](#bib3){ref-type="other"}), whereas another study including six NSCLC patients of Asian ethnicity reported a 100% concordance in regard to *EGFR* mutation status ([Matsumoto *et al*, 2006](#bib31){ref-type="other"}). This discrepancy could be related to the different sites of the metastatic tumours analysed in this study (five different distant metastases), whereas in the Matsumoto\'s *et al* study, only tumour samples from brain metastases were included. Diverse sites of metastases in NSCLC probably represent different clonal outgrowths. Alternatively, we cannot exclude that the different ethnicity of patients and/or the different types of *EGFR* mutations could be the reason for this discrepancy ([Tsao *et al*, 2006](#bib44){ref-type="other"}; [Pallis *et al*, 2007](#bib33){ref-type="other"}). In this study including only Caucasian patients, three classical activating (Del19 and E746V) and four non-classical mutations (T847A, L692P-V717A, L692P and G857E) were detected, whereas in Matsumoto\'s *et al* study, only classical activating Del19 and L858R mutations were reported. Concerning the non-classical mutations, it is unlikely to represent PCR artifacts, as L692F, T847I and G857E *EGFR* mutations have been previously reported ([Fujimoto *et al*, 2005](#bib14){ref-type="other"}; [Tsao *et al*, 2005](#bib45){ref-type="other"}; [Hsieh *et al*, 2006](#bib22){ref-type="other"}). Furthermore, the expression of phosphorylated EGFR (pY1173-EGFR-positive) on tumour cells from metastatic lesions carrying the T847A and L692P-V717A mutations strongly suggests that the former might be activating EGFR mutation. The time elapsed between diagnoses of the primary tumour and corresponding metastasis in patients (nos. 13 and 12) carrying the abovementioned mutations was 74.5 and 10 months, respectively. Therefore, acquisition of new mutations may be developed during the evolution of the metastatic process.

The administration of TKIs could be an additional explanation of the observed discordance of *EGFR* mutations. Three out of 25 patients received gefitinib before the development of a metachronous metastasis, whereas none of the patients reported in the Matsumoto\'s *et al* study had exposed to TKIs. It is known that NSCLC patients with EGFR-dependent primary tumours when treated with TKIs can develop metastases, in which either the EGFR signalling is negated or resistance is acquired due to secondary *EGFR* mutations like T790M or MET amplification ([Daneshmand *et al*, 2003](#bib10){ref-type="other"}; [Gazdar and Minna, 2005](#bib16){ref-type="other"}; [Engelman *et al*, 2007](#bib13){ref-type="other"}; [Lutterbach *et al*, 2007](#bib28){ref-type="other"}). It is interesting to note that in patients who had not been exposed to TKIs before biopsy of metastatic lesions, a 18% (4 out of 22 patients) discordance was observed between primary tumours and related metastases. However, a final explanation of the observed discordance, which cannot be excluded, concerns the low-frequency intratumoral heterogeneity for the occurrence of *EGFR* mutations ([Sakurada *et al*, 2008](#bib37){ref-type="other"}).

Our findings concerning the *K-RAS* mutation status are in agreement with a previous study demonstrating that the *K-RAS* mutational status of the primary tumour does not always predict the status of bone metastasis in NSCLC ([Badalian *et al*, 2007](#bib1){ref-type="other"}). A similar phenomenon was also reported in patients with colorectal cancer ([Tortola *et al*, 2001](#bib43){ref-type="other"}). Although *K-RAS* mutations seem to be associated with the early development of NSCLC, it cannot be excluded that *K-RAS* mutations are lost later during tumour progression ([Burmer and Loeb, 1989](#bib4){ref-type="other"}; [Li *et al*, 1994](#bib26){ref-type="other"}). This may, in part, explain the discordance in the *K-RAS* mutation status between primary tumours and metachronous metastases.

Another possibility for the observed discordance in the *EGFR* and *K-RAS* mutation status could be related to the administered chemotherapy. However, as shown in [Table 1](#tbl1){ref-type="table"}, among the 10 patients who had not received any treatment before the mutation analysis of the metastatic lesions, 5 developed metastases with different mutation status from that of the corresponding primary tumours. Thus, although tumour clone selection through the various treatments could be an explanation for the different molecular pattern in the primary tumour and metastatic site, our findings suggest that the metastasis genotype could be different from that of the corresponding primary tumour irrespectively of administered chemotherapy.

Previous studies have shown that *EGFR* and *K-RAS* mutations are mutually exclusive, suggesting the presence of different pathways of lung carcinogenesis. However, as previously reported, our data show that *K-RAS* mutation may coexist with *EGFR* mutation ([Fujimoto *et al*, 2005](#bib14){ref-type="other"}; [Han *et al*, 2006](#bib18){ref-type="other"}). Among the five patients with *EGFR* mutations in primary tumours, one patient concomitantly had *K-RAS* mutation (G12C with deletion in exon 19). In the metachronous metastasis, only the *K-RAS* mutation was retained. This patient received gefitinib after the biopsy of metastatic lesion and had stable disease lasting for 3.5 months. The limited duration of response is compatible with the knowledge that the presence of *K-RAS* mutations is associated with resistance to TKIs.

In this study, the expression of pY1173-EGFR was different between primary tumours and corresponding metastases in eight (50%) patients, whereas EGFR expression was discordant in two (10%) patients. The apparent lack of correlation between EGFR and p-EGFR expression has been previously reported and could be due to the different scoring systems and different sensitivities of antibodies used to evaluate the EGFR and p-EGFR expressions ([Han *et al*, 2005](#bib17){ref-type="other"}). It is well known that overexpression of *EGFR* is associated with Tyr phosphorylation of the receptor proteins and that mutations in the kinase domain may cause constitutive phosphorylation of EGFR ([Chen *et al*, 2006](#bib6){ref-type="other"}). However, biochemical studies have shown that variable phosphorylation rates were associated with different tyrosine phosphorylation sites in the receptor; G719S mutant receptor had less EGF-induced phosphorylation at Y845, Y992, Y1068 and Y1173 than did wild-type EGFR, whereas L858R mutant receptor preferentially phosphorylated at the Y1068 but not at Y1173 ([Sordella *et al*, 2004](#bib39){ref-type="other"}; [Chen *et al*, 2006](#bib6){ref-type="other"}; [Liu *et al*, 2007](#bib27){ref-type="other"}).

Clinical investigations suggested a correlation between a high *EGFR* gene copy number and *EGFR* mutations ([Cappuzzo *et al*, 2005](#bib5){ref-type="other"}; [Takano *et al*, 2005](#bib40){ref-type="other"}). Our study failed to demonstrate such a correlation probably due to limited number of cases analysed. Evaluable paired tissue specimens for fluorescence *in situ* hybridisation analysis were available for eight patients. Among them, two (nos 13 and 19) patients presented different *EGFR* mutation status in the primary tumours and corresponding metastases; however, these two patients harbour non-classical *EGFR* mutations (T847A and G857E) and did not show different *EGFR* amplification patterns between paired samples. On the basis of these findings, at the present time, we consider that only the genetic differences unequivocally distinguish EGFR-dependent tumours, which are likely to be sensitive to TKIs from the tumours that could be resistant to these agents ([Papadopoulos *et al*, 2006](#bib35){ref-type="other"}).

In conclusion, our findings indicate a substantial discordance of *EGFR* and *K-RAS* mutations between the primary tumours and the corresponding metastases in NSCLC and underline the need to consider the genotype of both primary and metastatic tumours for selecting patients who will respond to therapy with TKIs.

This study was supported by a research grant from the Cretan Association for Biomedical Research (CABR).

###### 

Patient\'s clinicopathological characteristics

  **Case**    **Age**   **Sex**  **Histology**    **Stage^a^**  **Smoking status**   **Tissue sample^b^ P^c^/M^d^**   **Metastatic site**    **Time^e^ elapsed between P and M**  **Treatment administered between P and M**
  ---------- --------- --------- --------------- -------------- -------------------- -------------------------------- --------------------- ------------------------------------- --------------------------------------------
  1             60         M     ADC                   IV       Active               B/B                              Skin                                   10                   Taxane--platinum
  2             54         M     SCC                   II       Active               S/S                              Lung                                   20                   None
  3             70         M     ADC                  III       Former               B/B                              Lung                                   55                   Taxane--gemcitabine
  4             44         M     ADC                  III       Active               S/B                              Lung                                   65                   Taxane--platinum--gemcitabine
  5             55         M     ADC                  III       Active               S/S                              Lung                                   23                   Taxane--platinum
  6             63         M     ADC                   IV       Active               B/B                              Lung                                    4                   None
  7             66         M     ADC/BAC              III       Never                S/B                              Thoracic wall                          12                   None
  8             57         M     LCC                  III       Active               S/B                              Thoracic wall                           4                   Taxane--platinum
  9             55         M     ADC                  III       Former               S/S                              Thoracic wall                          15                   Taxane--platinum
  10            49         M     ADC                   II       Active               S/S                              Adrenal gland                          28                   Taxane--platinum
  11            50         F     ADC                   IV       Active               B/B                              Brain                                  36                   Taxane--platinum
  12            68         M     ADC                  III       Active               S/S                              Brain                                  10                   Taxane--platinum
  13            44         M     GCC                   IV       Active               B/B                              Lung                                   74                   Taxane--platinum
  14            56         M     ADC                   IV       Active               B/S                              Adrenal gland                          17                   None
  15            53         M     ADC                  III       Active               S/B                              Thoracic wall                           2                   Taxane--platinum
  16            41         M     ADC                   IV       Active               S/B                              Lung                                   143                  None
  17            56         M     ADC                   IV       Former               B/S                              Adrenal gland                          36                   Taxane--platinum--gemcitabine, gefitinib
  18            42         F     ADC                   II       Never                S/S                              Liver                                  30                   Taxane--platinum, gefitinib
  19            55         M     ADC                  III       Former               S/B                              Bone                                    2                   None
  20            46         M     SCC                  III       Active               S/B                              Lung                                   45                   Taxane--platinum--gefitinib
  21            62         M     LCC                  III       Never                S/B                              Bone                                   48                   Platinum--gemcitabine
  22            67         M     ADC                   IV       Active               B/S                              Adrenal gland                          14                   None
  23            53         M     ADC                   IV       Active               S/B                              Brain                                  21                   None
  24            52         F     ADC/BAC               II       Active               S/S                              Lung                                   51                   None
  25            63         M     ADC                   IV       Active               B/B                              Thoracic wall                           1                   None

ADC=adenocarcinoma; ADC/BAC=adenocarcinoma with bronchoalveolar features; GCC=giant cell carcinoma; LCC=large cell carcinoma; F=female; M=male; SCC=squamous carcinoma.

Stage, corresponds to that of the time of primary diagnosis.

Tissue sample: B, biopsy; S, surgery.

P, primary tumour.

M, metastasis.

Time, months.

###### 

*EGFR* and *K-RAS* status in paired primary and metastatic tumours

       ***EGFR* mutation status**   **EGFR expression**    **p-EGFR expression**   ***K-RAS* mutation status**                                
  ---- ---------------------------- --------------------- ----------------------- ----------------------------- ---- ---- ------ ------ ----- -----
  1    wt                           wt                              1+                         1+                0    2+  wt     wt     No    ---
  2    wt                           wt                              3+                         3+                1+   1+  wt     wt     No    ---
  3    wt                           wt                               0                         1+                0    0   wt     wt     No    ---
  4    wt                           wt                              3+                         2+                0    1+  wt     wt     No    ---
  5    wt                           wt                               0                          0                0    0   wt     wt     No    ---
  6    wt                           wt                              1+                          0                0    0   wt     wt     No    ---
  7    wt                           wt                               0                         1+                0    0   wt     wt     No    ---
  8    wt                           wt                              1+                          0                0    0   G12S   wt     No    ---
  9    wt                           wt                              1+                         1+                0    1+  wt     G13S   No    ---
  10   wt                           wt                              2+                         3+                0    0   G12V   G12V   No    ---
  11   wt                           wt                              ND                         2+                ND   2+  wt     G12S   No    ---
  12   wt                           L692P V717A                     1+                          0                ND   2+  wt     wt     No    ---
  13   wt                           T847A                            0                          0                0    1+  wt     wt     No    ---
  14   wt                           wt                              3+                          0                1+   0   wt     wt     Yes   PD
  15   wt                           wt                               0                         2+                ND   2+  wt     wt     Yes   PD
  16   wt                           wt                               0                          0                0    2+  wt     G12A   Yes   PD
  17   L692P                        wt                               0                         1+                0    0   wt     wt     Yes   SD
  18   E746V                        wt                               0                          0                ND   0   wt     wt     Yes   SD
  19   G857E                        wt                               0                          0                0    1+  wt     wt     Yes   SD
  20   E746-A750 del                E746-A750 del T790M             2+                         3+                2+   0   wt     wt     Yes   SD
  21   wt                           wt                              ND                         ND                ND   ND  wt     wt     No    ---
  22   wt                           wt                              ND                         ND                ND   ND  G12D   wt     Yes   PD
  23   E746-A750 del                wt                              ND                         ND                ND   ND  G12C   G12C   Yes   SD
  24   wt                           wt                              ND                         ND                ND   ND  wt     wt     No    ---
  25   wt                           wt                              ND                         ND                ND   ND  G12C   wt     No    ---

###### 

Combined analysis of *EGFR* and *K-RAS* mutation status

           **Primary/metastatic tumour**                                  
  ------- ------------------------------- --------- --------- ----------- ---------------
  EGFR               18 (72%)              2 (8%)    4 (16%)   1 (4%)^a^   7 cases (28%)
  K-RAS              17 (68%)              3 (12%)   3 (12%)    2 (8%)     6 cases (24%)

Del19/Del19 and T790M.

###### 

EGFR expression as assessed by IHC

                    **Primary tumour status/metastasis status**                                       
  ---------------- --------------------------------------------- ------------ ----------- ----------- --------------
  EGFR                               4 (21.1%)                    13 (68.4%)   1 (5.3%)    1 (5.3%)    2/19 (10.6%)
  p-EGFR (Y1173)                     1 (6.2%)                     7 (43.8%)    2 (12.5%)   6 (37.5%)    8/16 (50%)

IHC=immunohistochemistry.
